The targeting of LOX enzymes, using function-blocking mAbs, has long shown promise in normalising a pathologically stiff ECM in mouse xenografts and fibrosis models [157,158]; the targeting of LOX can reduce stiffness, desmoplasia, invasion, and metastasis. This evidence concerns the gene LOX and fibrosis.